CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英国血液学会套细胞淋巴瘤管理指南 2018 增补 (Br. J. Haematol. 2018; 182: 46-62)：接受共价布鲁顿酪氨酸激酶抑制剂治疗复发/难治性疾病的潜在 CAR-T 候选者的风险评估
英文原题：Addendum to British Society for Haematology Guideline for the management of mantle cell lymphoma, 2018 (Br. J. Haematol. 2018; 182: 46-62): Risk assessment of potential CAR T candidates receiving a covalent Bruton tyrosine kinase inhibitor for relapsed/refractory disease.
查看英文原题
Addendum to British Society for Haematology Guideline for the management of mantle cell lymphoma, 2018 (Br. J. Haematol. 2018; 182: 46-62): Risk assessment of potential CAR T candidates receiving a covalent Bruton tyrosine kinase inhibitor for relapsed/refractory disease.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
摘要
这条来源本身就没有摘要（PubMed 未提供），不是「还没翻译」。可以点最下面的「在 PubMed 查看」打开原文献页面。
论文信息
- 作者
- O'Reilly MA、Sanderson R、Wilson W、Iyengar S、Lambert J、McCulloch R、Eyre TA、BSH Guidelines Committee Haemato-oncology Task Force
- 第一作者单位
- Department of Haematology, University College London Hospitals NHS Foundation Trust, London, UK.United Kingdom
- 通讯作者单位
- Department of Haematology, Oxford University NHS Trust, Oxford, UK.United Kingdom
- 文献类型
- 临床实践指南
- 期刊
- British journal of haematology2022 Oct
- 原文标识
- PubMed 35894253 · DOI 10.1111/bjh.18378